RxDoctor Payments Data

Jennifer McManus

Family · Waldorf, MDNPI 1689919961

Payments from drug & device makers

$5,302in general payments, 2019–2025

Across 293 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$937
  • AbbVie$822
  • Lilly USA, LLC$541
  • Novo Nordisk$508
  • Alkermes, Inc.$335
  • Abbott$184
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,287100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,302 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$67,174
Medicare patients
178
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$55,560
Tresiba Flextouch U-200Insulin Degludec46$30,188
ZubsolvBuprenorphine Hcl/Naloxone Hcl28$17,843
LinzessLinaclotide17$10,981
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$3,416
Potassium Chloride14$2,403
Carbamazepine13$1,738
Novolog FlexpenInsulin Aspart12$1,587
Rosuvastatin Calcium69$1,522
Ezetimibe28$1,172
Levothyroxine Sodium128$1,086
Atorvastatin Calcium115$1,074
Vilazodone Hcl13$1,046
Duloxetine Hcl25$987
Nifedipine ErNifedipine38$951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$508$55,56030 claims
Orexo US, Inc.Zubsolv$173$17,84328 claims
AbbVieLinzess, Synthroid$822$11,50733 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$13$3,41637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Waldorf

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →